Journal of the American College of Cardiology
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B
Trial in peopleInterventions
Papers by Martha A. Grogan
8 results
- Journal of the American Heart Association
Utility of Prognostic Staging Systems in Transthyretin Amyloidosis Cardiomyopathy in the Era of Available Disease-Modifying Treatment
Study in peopleBiomarkers - AHA Scientific Sessions 2025 Abstract
Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results From the ATTRibute-CM Study
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient Subgroups
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients With Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Trial in peopleInterventions